Investors in digital health are a different breed. They invest less than life science investors, and they expect (and receive) more rapid returns. What's more, the corporate, strategic investment funds are not simply the venture arms of big pharma and medtech; health insurers and the tech firms are in there, too. And, guess what – they have entirely different agendas.
In Vivo has looked at 267 venture capital investments in digital health in 2017 with a composite value of $6.13 billion. The analysis looks at patterns of investments, what kind of companies are getting funded, and the nature of the investing participants.
A few observations stand out immediately: